Article
Utilization, Cost, and Prescription Trends of Antipsychotics Prescribed by Dermatologists for Medicare Patients
- Author:
- Kush Maheshwari, MD
- Yu Wang, MD
- John R. Edminister, MD
- Wasim Haidari, MD
- Lindsy Pang, MD
- Steven R. Feldman, MD, PhD
To the Editor:
Patients with primary psychiatric disorders with dermatologic manifestations often seek treatment from dermatologists instead...
Article
Commentary: Topical Treatments for AD and Possible Lifestyle Adjustments, July 2024
- Author:
- Steven R. Feldman, MD, PhD
Publish date: June 28, 2024
Article
Commentary: Interrelationships Between AD and Other Conditions, June 2024
- Author:
- Steven R. Feldman, MD, PhD
Publish date: May 16, 2024
Article
Commentary: Studies Often Do Not Answer Clinical Questions in AD, May 2024
- Author:
- Steven R. Feldman, MD, PhD
Publish date: April 25, 2024
Article
Commentary: Choosing Treatments of AD, and Possible Connection to Learning Issues, April 2024
- Author:
- Steven R. Feldman, MD, PhD
Publish date: March 26, 2024
Article
Commentary: Drug Comparisons and Contact Allergy in AD, February 2024
- Author:
- Steven R. Feldman, MD, PhD
Publish date: January 24, 2024
Article
Commentary: JAK Inhibitors and Comorbidities in AD, December 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: November 21, 2023
Article
Commentary: New and old treatments for AD, November 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: October 31, 2023
Article

Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Dual Biologic Therapy
- Author:
- Margaret A. Kaszycki, MD
- Jessica N. Pixley, MD
- Steven R. Feldman, MD, PhD
Atopic dermatitis and psoriasis can coexist in a single patient, which may be suspected from a clinical picture of treatment-resistant disease, a...
Article
Commentary: Are "significant" results necessarily clinically meaningful? October 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: September 20, 2023
Article
Commentary: Newer Drugs for AD Plus Dupilumab and Other Issues, September 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: August 24, 2023
Article
Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: July 31, 2023
Article
Commentary: Topical treatments, dupilumab, and long-term treatment of AD, July 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: June 22, 2023
Article
Commentary: Topical treatments, dupilumab, and long-term treatment of AD, July 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: June 22, 2023
Article
Commentary: AD, RA, Probiotics, and a New JAK inhibitor, June 2023
- Author:
- Steven R. Feldman, MD, PhD
Publish date: May 30, 2023